Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

This is a preview of updates coming to the Technical Bulletin's website in April 2026. Return to current site.
Read more about the modernization release schedule in this announcement.
Comment via the yellow feedback button in the lower right hand corner of the page. Contact the NLM Help Desk with any questions or concerns.

This is archived content.

Links may have become inactive over time. Visit Archive-It   to find the original published layout.

RxNorm July 2022 Release

RxNorm July 2022 Release. NLM Tech Bull. 2022 Jul-Aug;(447):b2.

July 05, 2022 [posted]

The RxNorm July 2022 monthly release became available on Tuesday, July 5, 2022, and includes a new dose form "Drug-Eluting Contact Lens" and a new concept for Lagevrio, which is a brand name COVID-19 medication.

RxNorm Data Changes

New Dose Form

RxNorm includes a new dose form: Drug-Eluting Contact Lens. This dose form is defined as a contact lens intended for use in the eye that releases a medication.

Here are the fully specified product name concepts with the new dose form "Drug-Eluting Contact Lens" in the July 2022 release:

RXCUI Term Type (TTY) STRING
2604045 SCD ketotifen 0.019 MG Drug-Eluting Contact Lens
2604049 SBD ketotifen 0.019 MG Drug-Eluting Contact Lens [Acuvue Theravision]

Lagevrio COVID-19 Medication Concept Added

The molnupiravir COVID-19 medication will be available under the brand name Lagevrio. To reflect this change, a Semantic Branded Drug (SBD) concept for Lagevrio is included in the RxNorm July monthly release. The National Drug Codes (NDCs) for Lagevrio were previously associated with the generic molnupiravir drug concept. NDCs moved from RXCUI 2587906 to RXCUI 2603740. Get more information about Lagevrio from the U.S. Food and Drug Administration (FDA).

Here is the new Lagevrio COVID-19 medication concept in RxNorm:

RXCUI Term Type (TTY) STRING
2603740 SBD molnupiravir 200 MG Oral Capsule [Lagevrio]